Investigational new drugs: FDA's expanded access program : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives
United States. Government Accountability Office, issuing body.
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health, issuing body.
Publication:
Washington, D.C. : U.S. Government Accountability Office, October 3, 2017